BioNTech and Genentech Terminate Phase II autogene cevumeran Trial in Resected Colorectal Cancer After OS Imbalance Favors Control
核心洞察
BioNTech and Genentech terminated the Phase II BNT122-01 trial of autogene cevumeran in resected colorectal cancer (搜索) after a DSMB found an overall survival imbalance favoring the control arm.
The DSMB had previously flagged futility in October 2025 but allowed the trial to continue, concluding the data were too immature for reliable efficacy conclusions.
No new safety signals were identified, and the pancreatic cancer program IMcode003 testing autogene cevumeran with atezolizumab and mFOLFIRINOX continues as planned.
BioNTech SE and Genentech, a member of the Roche Group, have terminated the Phase II BNT122-01 trial of autogene cevumeran in resected colorectal cancer (搜索) after an independent data safety monitoring board identified a numerical imbalance in overall survival favoring the control arm. The company announced the decision on Aug. 28, 2026.
The finding goes beyond the futility signal the DSMB had flagged in October 2025. At that earlier review, the board concluded the data were too immature to support reliable efficacy conclusions and did not recommend stopping the trial. At its most recent review, the DSMB determined that further continuation was unlikely to change the outcome. No new safety signals were identified.
BioNTech said full trial data will be shared with the scientific community at a future date. The magnitude, statistical significance and causes of the overall survival imbalance have not been disclosed.
Trial Design and Patient Population
BNT122-01 enrolled patients with circulating tumor DNA (ctDNA)-positive, surgically resected Stage II (high risk) or Stage III colorectal cancer (搜索). The trial compared autogene cevumeran as adjuvant monotherapy against watchful waiting, the current standard of care.
Autogene cevumeran is a uridine mRNA-lipoplex nanoparticle vaccine encoding patient-specific tumor neoantigens identified through tumor sequencing. It is designed to train T cells to recognize and attack residual cancer cells. The monotherapy design was a deliberate test of whether the vaccine alone, without checkpoint inhibitor support, could prevent recurrence in a molecularly selected population.
An Immunological Obstacle in Cold Tumors
The failure reflects a well-established immunological obstacle. Colorectal cancer (搜索) is predominantly microsatellite stable (MSS), a subtype characterized by low mutational burden and an immunosuppressive tumor microenvironment that has consistently resisted checkpoint inhibition. Using ctDNA positivity as a selection biomarker was intended to enrich for patients at highest recurrence risk, but that enrichment strategy could not overcome the immunological hostility of MSS colorectal cancer to T cell-based approaches.
The overall survival imbalance, if confirmed in the final analysis, would represent a more concerning outcome than futility alone.
This is the second discontinuation for autogene cevumeran in a solid tumor indication outside pancreatic cancer. Earlier in 2026, BioNTech and Roche discontinued the Phase II IMcode004 trial evaluating autogene cevumeran plus nivolumab in adjuvant muscle-invasive urothelial carcinoma (搜索), citing a rapidly shifting treatment landscape.
Pancreatic Program Continues
The pancreatic ductal adenocarcinoma (搜索) (PDAC) program remains the asset's primary clinical rationale. The Phase II IMcode003 trial evaluating autogene cevumeran in combination with Roche's Tecentriq (atezolizumab) and mFOLFIRINOX chemotherapy in adjuvant PDAC is unaffected and continues as planned.
That trial's combination design directly addresses the limitation exposed in BNT122-01 by pairing the vaccine with checkpoint inhibition and cytotoxic chemotherapy to overcome the immunosuppressive microenvironment rather than relying on the vaccine alone. Phase I data in resected PDAC showed persistent neoantigen-specific T cell responses at three years and longer recurrence-free survival in vaccine responders, supporting the biological rationale for the combination approach.
BioNTech co-founder and Chief Medical Officer Özlem Türeci said the outcome "provides scientific insight into the challenges of treating immunotherapy-insensitive tumor types with immune-suppressive microenvironments." She added that the company remains committed to mRNA as a key pillar in its oncology strategy and to novel combination approaches.
BioNTech said it will conduct a thorough analysis of the BNT122-01 data to inform future development strategy for mRNA cancer immunotherapies in immunologically cold tumor types. The company continues to advance other experimental mRNA cancer vaccines targeting head and neck cancer and non-small cell lung cancer (搜索).
Mixed Signals Across the Field
The BNT122-01 result arrives against a backdrop of mixed signals for the personalized mRNA vaccine field. Moderna and Merck (搜索)'s Phase III INTerpath-001 trial of intismeran autogene (mRNA-4157) plus Merck's Keytruda (pembrolizumab) met its primary and a key secondary endpoint in resected Stage IIB-IV melanoma (搜索), a result achieved in a combination setting with checkpoint inhibition.
That success, and the failure in BNT122-01, together reinforce the view that personalized mRNA vaccines require immune priming support to deliver clinical benefit, particularly in immunologically cold tumor types. Melanoma (搜索) is a "hot" tumor for which the body's immune system mounts a significant natural response, unlike colorectal and pancreatic cancer.
In adjuvant PDAC, Boston-based Elicio Therapeutics reported in June 2026 that its off-the-shelf KRAS peptide vaccine ELI-002 7P missed its primary endpoint in the intent-to-treat population, though a post-hoc analysis in completely resected patients suggested a disease-free survival benefit.
BioNTech's pipeline also features other cancer therapies. The company recently announced that one of them, gotistibart (搜索), nearly doubled the median overall survival compared with chemotherapy in previously treated patients with squamous non-small cell lung cancer (搜索).